Evidence map›Paper›PMID 31493950›Full record

ArticleVaccine2019

Comparison of adjuvants to optimize influenza neutralizing antibody responses.

Rebecca S Rudicell, Marie Garinot, Masaru Kanekiyo, Heather D Kamp, Kurt Swanson, Te-Hui Chou, Shujia Dai, Olivier Bedel, Daniel Simard, Rebecca A Gillespie and 16 more

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 4 institutions in 2 countries.

Rebecca S RudicellSanofi, Cambridge, MA, USA.
Marie GarinotSanofi Pastuer, Cambridge, MA, USA.
Masaru KanekiyoVaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Heather D KampSanofi, Cambridge, MA, USA.
Kurt SwansonSanofi, Cambridge, MA, USA.
Te-Hui ChouSanofi, Cambridge, MA, USA.
Shujia DaiSanofi, Cambridge, MA, USA.
Olivier BedelSanofi, Cambridge, MA, USA.
Daniel SimardSanofi, Cambridge, MA, USA.
Rebecca A GillespieVaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kanwen YangSanofi, Cambridge, MA, USA.
Michael ReardonSanofi, Cambridge, MA, USA.
Luis Z AvilaSanofi, Cambridge, MA, USA.
Magnus BesevSanofi, Cambridge, MA, USA.
Pradeep K DhalSanofi, Cambridge, MA, USA.
Ram DharanipragadaSanofi, Cambridge, MA, USA.
Lingyi ZhengSanofi Pastuer, Cambridge, MA, USA.
Xiaochu DuanSanofi Pastuer, Cambridge, MA, USA.
Joshua DinapoliSanofi Pastuer, Cambridge, MA, USA.
Thorsten U VogelSanofi Pastuer, Cambridge, MA, USA.
Harry KleanthousSanofi Pastuer, Cambridge, MA, USA.
John R MascolaVaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Barney S GrahamVaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jean HaenslerSanofi Pastuer, Cambridge, MA, USA.
Chih-Jen WeiSanofi, Cambridge, MA, USA. Electronic address: Chih-Jen.Wei@sanofi.com.
Gary J NabelSanofi, Cambridge, MA, USA. Electronic address: Gary.Nabel@sanofi.com.
Sanofi (United States) · USNational Institutes of Health · USAVEO Oncology (United States) · USSanofi (France) · FR

Funding

Influenza Vaccine Research and DevelopmentZIAAI005003 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KANEKIYO, MASARU · 2009 to 2025
$89.8M
Intramural NIH HHS ZIA AI005003
6 · The paper itself

Abstract

Seasonal influenza vaccines represent a positive intervention to limit the spread of the virus and protect public health. Yet continual influenza evolution and its ability to evade immunity pose a constant threat. For these reasons, vaccines with improved potency and breadth of protection remain an important need. We previously developed a next-generation influenza vaccine that displays the trimeric influenza hemagglutinin (HA) on a ferritin nanoparticle (NP) to optimize its presentation. Similar to other vaccines, HA-nanoparticle vaccine efficacy is increased by the inclusion of adjuvants during immunization. To identify the optimal adjuvants to enhance influenza immunity, we systematically analyzed TLR agonists for their ability to elicit immune responses. HA-NPs were compatible with nearly all adjuvants tested, including TLR2, TLR4, TLR7/8, and TLR9 agonists, squalene oil-in-water mixtures, and STING agonists. In addition, we chemically conjugated TLR7/8 and TLR9 ligands directly to the HA-ferritin nanoparticle. These TLR agonist-conjugated nanoparticles induced stronger antibody responses than nanoparticles alone, which allowed the use of a 5000-fold-lower dose of adjuvant than traditional admixtures. One candidate, the oil-in-water adjuvant AF03, was also tested in non-human primates and showed strong induction of neutralizing responses against both matched and heterologous H1N1 viruses. These data suggest that AF03, along with certain TLR agonists, enhance strong neutralizing antibody responses following influenza vaccination and may improve the breadth, potency, and ultimately vaccine protection in humans.

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, NeutralizingFemaleHEK293 CellsHemagglutination Inhibition TestsHemagglutininsHumansInfluenza VaccinesMacaca mulattaMice, Inbred BALB CNanoparticlesToll-Like ReceptorsAdjuvants, ImmunologicAntibodies, NeutralizingHemagglutininsInfluenza VaccinesToll-Like ReceptorsAdjuvantsAF03Influenza vaccineNanoparticlesSTING agonistsTLR agonists

Identifiers

PMID31493950
PMCPMC6771022
OpenAlexW2972020555

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.